Clinical Trial Update: Study of HIV Patients With Undetectable Viral Load and Abnormal Lipids Switching to Atazanavir/Ritonavir [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating switching HIV patients with undetectable viral load and abnormal lipids to the fixed-dose combination of atazanavir/ritonavir.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Infection

Drugs mentioned

• Atazanavir/ritonavir (atazanavir/ritonavir)

Snippet

Sponsor: Bristol-Myers Squibb | Conditions: HIV Infections | Phase 3 | Status: COMPLETED